Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 48 papers were listed this time. Here's a few in our areas of research interest:
Gajic-Veljanoski O, Bayoumi AM, Tomlinson G, et al. Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted? Osteoporos Int. 2012 Mar 8. [Epub ahead of print] PubMed PMID: 22398856.
Erhardt W, Bergenheim K, Duprat-Lomon I, at al. Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany: A Cardiff Diabetes Model Analysis. Clin Drug Investig. 2012 Mar 1;32(3):189-202. PubMed PMID: 22292415.
Valentine WJ, Jendle J, Saraheimo M, et al. Evaluating the cost- effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med. 2012 Mar;29(3):303-12. PubMed PMID: 21951030.
Davies MJ, Chubb BD, Smith IC, et al. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med. 2012 Mar;29(3):313-20. PubMed PMID: 21883438.
De Smedt D, De Cocker K, Annemans L, et al. A cost-effectiveness study of the community-based intervention '10 000 Steps Ghent'. Public Health Nutr. 2012 Mar;15(3):442-51. Epub 2011 Aug 23. PubMed PMID: 21859505.